Takeda Pharmaceutical Co. Ltd.
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Take… Read more
Market Cap & Net Worth: Takeda Pharmaceutical Co. Ltd. (TKPHF)
Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF) has a market capitalization of $47.50 Billion ($47.50 Billion) as of March 19, 2026. Listed on the PINK stock exchange, this USA-based company holds position #457 globally and #364 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Takeda Pharmaceutical Co. Ltd.'s stock price $30.07 by its total outstanding shares 1579596411 (1.58 Billion).
Takeda Pharmaceutical Co. Ltd. Market Cap History: 2015 to 2025
Takeda Pharmaceutical Co. Ltd.'s market capitalization history from 2015 to 2025. Data shows change from $54.17 Billion to $47.50 Billion (-0.73% CAGR).
Takeda Pharmaceutical Co. Ltd. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Takeda Pharmaceutical Co. Ltd.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.01x
Takeda Pharmaceutical Co. Ltd.'s market cap is 0.01 times its annual revenue
1.02x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
0.44x
Takeda Pharmaceutical Co. Ltd.'s market cap is 0.44 times its annual earnings
10.35x
Lower than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $45.07 Billion | $1.81 Trillion | $80.17 Billion | 0.02x | 0.56x |
| 2017 | $63.70 Billion | $1.73 Trillion | $114.94 Billion | 0.04x | 0.55x |
| 2018 | $39.02 Billion | $1.77 Trillion | $186.89 Billion | 0.02x | 0.21x |
| 2019 | $47.49 Billion | $2.10 Trillion | $109.13 Billion | 0.02x | 0.44x |
| 2020 | $45.31 Billion | $3.29 Trillion | $44.24 Billion | 0.01x | 1.02x |
| 2021 | $35.18 Billion | $3.20 Trillion | $376.00 Billion | 0.01x | 0.09x |
| 2022 | $42.92 Billion | $3.57 Trillion | $230.06 Billion | 0.01x | 0.19x |
| 2023 | $42.37 Billion | $4.03 Trillion | $317.02 Billion | 0.01x | 0.13x |
| 2024 | $40.12 Billion | $4.26 Trillion | $144.07 Billion | 0.01x | 0.28x |
| 2025 | $47.50 Billion | $4.58 Trillion | $107.93 Billion | 0.01x | 0.44x |
Competitor Companies of TKPHF by Market Capitalization
Companies near Takeda Pharmaceutical Co. Ltd. in the global market cap rankings as of March 19, 2026.
Key companies related to Takeda Pharmaceutical Co. Ltd. by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #410 globally with a market cap of $53.52 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #721 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
- United Therapeutics Corporation (NASDAQ:UTHR): Ranked #917 globally with a market cap of $21.42 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #410 | Zoetis Inc | NYSE:ZTS | $53.52 Billion | $121.68 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.60 |
| #721 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
| #917 | United Therapeutics Corporation | NASDAQ:UTHR | $21.42 Billion | $540.02 |
Takeda Pharmaceutical Co. Ltd. Historical Marketcap From 2015 to 2025
Between 2015 and today, Takeda Pharmaceutical Co. Ltd.'s market cap moved from $54.17 Billion to $ 47.50 Billion, with a yearly change of -0.73%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $47.50 Billion | +18.39% |
| 2024 | $40.12 Billion | -5.30% |
| 2023 | $42.37 Billion | -1.29% |
| 2022 | $42.92 Billion | +22.02% |
| 2021 | $35.18 Billion | -22.37% |
| 2020 | $45.31 Billion | -4.58% |
| 2019 | $47.49 Billion | +21.69% |
| 2018 | $39.02 Billion | -38.75% |
| 2017 | $63.70 Billion | +41.34% |
| 2016 | $45.07 Billion | -16.79% |
| 2015 | $54.17 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Takeda Pharmaceutical Co. Ltd. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $47.50 Billion USD |
| MoneyControl | $47.50 Billion USD |
| MarketWatch | $47.50 Billion USD |
| marketcap.company | $47.50 Billion USD |
| Reuters | $47.50 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.